Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza ...

Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao Manabe, DVM, PhD, will continue to serve as representative director and ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

With a sustained 7% annual growth rate, the CDMO sector reflects a fundamental shift in how modern medicines are brought to ...

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

Thank you very much for waiting. We will now would like to start Daiichi Sankyo's Financial Results Briefing for the Third Quarter of Fiscal Year 2024. My name is Asakura from Corporate ...

IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...

Delhi: IHH Healthcare, a prominent global healthcare provider, has escalated its legal battle with Japan's Daiichi Sankyo, ...